Novo Nordisk A S annual return on equity
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Return on Equity (ROE) Growth & History (NVO)
Novo Nordisk A S's return on equity was 60.70% for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 60.70% | −20.08 pp |
| 2024 | 2024-12-31 | 80.78% | −7.29 pp |
| 2023 | 2023-12-31 | 88.07% | +16.06 pp |
| 2022 | 2022-12-31 | 72.00% | +0.76 pp |
| 2021 | 2021-12-31 | 71.24% | +1.54 pp |
| 2020 | 2020-12-31 | 69.70% | — |
Novo Nordisk A S quarterly return on equity
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.89% | −7.12 pp |
| Q1 2026 | 2026-03-31 | 24.46% | — |
| Q4 2025 | 2025-12-31 | 14.78% | −7.80 pp |
| Q3 2025 | 2025-09-30 | 11.84% | — |
| Q2 2025 | 2025-06-30 | 17.01% | — |
| Q4 2024 | 2024-12-31 | 22.58% | — |
Novo Nordisk A S return on equity trends
Over the last five fiscal years, Novo Nordisk A S's return on equity decreased from 69.70% to 60.70%, a change of −9.00 percentage points. The latest reported quarter, Q2 2026, shows 9.89%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...